Inoviq (ASX:IIQ) Receivables Turnover : 0.32 (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Inoviq Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Inoviq's Revenue for the six months ended in Dec. 2023 was A$0.20 Mil. Inoviq's average Accounts Receivable for the six months ended in Dec. 2023 was A$0.61 Mil. Hence, Inoviq's Receivables Turnover for the six months ended in Dec. 2023 was 0.32.

Inoviq Receivables Turnover Historical Data

The historical data trend for Inoviq's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inoviq Receivables Turnover Chart

Inoviq Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Receivables Turnover

Get a 7-Day Free Trial

1.24

0.86

1.46

Inoviq Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Receivables Turnover	Get a 7-Day Free Trial															0.08	0.28	0.24	0.34	0.32

Competitive Comparison of Inoviq's Receivables Turnover

For the Diagnostics & Research subindustry, Inoviq's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inoviq's Receivables Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Inoviq's Receivables Turnover falls into.

Inoviq Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Inoviq's Receivables Turnover for the fiscal year that ended in Jun. 2023 is calculated as

	Receivables Turnover (A: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Jun. 2023 )	/ (	(Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )
=	0.398	/ (	(0.267	+	0.28)	/	2 )
=	0.398	/	0.2735
=	1.46

Inoviq's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Jun. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	0.198	/ (	(0.28	+	0.948)	/	2 )
=	0.198	/	0.614
=	0.32

Inoviq (ASX:IIQ) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Inoviq Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Inoviq's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Inoviq (ASX:IIQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inoviq Ltd (ASX:IIQ) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168

Website

https://www.bard1.com

Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

Inoviq (ASX:IIQ) Headlines

No Headlines